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Research Epigenomic diversity of colorectal cancer indicated 
by LINE-1 methylation in a database of 869 tumors
Yoshifumi Baba†1, Curtis Huttenhower†2, Katsuhiko Nosho†1, Noriko Tanaka†1,2, Kaori Shima1, Aditi Hazra3,4, 
Eva S Schernhammer3,4,5, David J Hunter3,4, Edward L Giovannucci3,4,6, Charles S Fuchs1,4 and Shuji Ogino*1,7
Abstract
Background: Genome-wide DNA hypomethylation plays a role in genomic instability and carcinogenesis. LINE-1 (L1 
retrotransposon) constitutes a substantial portion of the human genome, and LINE-1 methylation correlates with 
global DNA methylation status. LINE-1 hypomethylation in colon cancer has been strongly associated with poor 
prognosis. However, whether LINE-1 hypomethylators constitute a distinct cancer subtype remains uncertain. Recent 
evidence for concordant LINE-1 hypomethylation within synchronous colorectal cancer pairs suggests the presence of 
a non-stochastic mechanism influencing tumor LINE-1 methylation level. Thus, it is of particular interest to examine 
whether its wide variation can be attributed to clinical, pathologic or molecular features.
Design: Utilizing a database of 869 colorectal cancers in two prospective cohort studies, we constructed multivariate 
linear and logistic regression models for LINE-1 methylation (quantified by Pyrosequencing). Variables included age, 
sex, body mass index, family history of colorectal cancer, smoking status, tumor location, stage, grade, mucinous 
component, signet ring cells, tumor infiltrating lymphocytes, CpG island methylator phenotype (CIMP), microsatellite 
instability, expression of TP53 (p53), CDKN1A (p21), CTNNB1 (β-catenin), PTGS2 (cyclooxygenase-2), and FASN, and 
mutations in KRAS, BRAF, and PIK3CA.
Results: Tumoral LINE-1 methylation ranged from 23.1 to 90.3 of 0-100 scale (mean 61.4; median 62.3; standard 
deviation 9.6), and distributed approximately normally except for extreme hypomethylators [LINE-1 methylation < 40; 
N = 22 (2.5%), which were far more than what could be expected by normal distribution]. LINE-1 extreme 
hypomethylators were significantly associated with younger patients (p = 0.0058). Residual plot by multivariate linear 
regression showed that LINE-1 extreme hypomethylators clustered as one distinct group, separate from the main 
tumor group. The multivariate linear regression model could explain 8.4% of the total variability of LINE-1 methylation 
(R-square = 0.084). Multivariate logistic regression models for binary LINE-1 hypomethylation outcomes (cutoffs of 40, 
50 and 60) showed at most fair predictive ability (area under receiver operator characteristics curve < 0.63).
Conclusions: LINE-1 extreme hypomethylators appear to constitute a previously-unrecognized, distinct subtype of 
colorectal cancers, which needs to be confirmed by additional studies. Our tumor LINE-1 methylation data indicate 
enormous epigenomic diversity of individual colorectal cancers.
Introduction
DNA methylation is a major epigenetic mechanism in X-
chromosome inactivation, imprinting and repression of
transposable elements and endogenous retroviral
sequences [1]. Global DNA hypomethylation appears to
play an important role in genomic instability [2,3], lead-
ing to cancer development [4-8]. Since LINE-1 or L1 ret-
rotransposon constitutes a substantial portion
(approximately 17%) of the human genome [9], the meth-
ylation status of LINE-1 reflects the global DNA methyla-
tion level. Prior studies have shown that tumor LINE-1
methylation correlates with cellular 5-methylcytocine
level in cancer tissues [10-12].
In addition to the role as a surrogate marker for global
DNA methylation, LINE-1 methylation status by itself
likely has biological effects, since retrotransposons such
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as LINE-1 elements can provide alternative promoters
[13], and contribute to non-coding RNA expression that
regulates functions of a number of genes [14,15]. More-
over, retrotransposons activated by DNA hypomethyla-
tion may transpose themselves throughout the genome,
leading to gene disruptions [16] and chromosomal insta-
bility [4,17]. LINE-1 methylation has been shown to be
highly variable among colon cancers [18,19], and LINE-1
hypomethylation is strongly associated with poor prog-
nosis in colon cancer [20]. However, whether LINE-1
hypomethylators constitute a distinct tumor subtype
remains uncertain. Our recent study has shown a signifi-
cant correlation of LINE-1 methylation levels within syn-
chronous colorectal cancer pairs (i.e., two or more
primary tumors in one patient), which suggests the pres-
ence of genetic and/or environmental factors influencing
LINE-1 methylation levels that are unlikely the result of a
purely stochastic phenomenon [21]. Therefore, there are
two distinct phenomena - a wide variation of LINE-1
methylation in colorectal cancers and a significant con-
cordance of LINE-1 methylation within synchronous col-
orectal cancer pairs - raising the intriguing question of
whether this wide variation of tumoral LINE-1 methyla-
tion can be explained by various clinical, pathologic or
molecular variables.
To address this question, we conducted this study with
a large database (N = 869) of colorectal cancers identified
in two prospective cohort studies and multivariate linear
and logistic regression models for LINE-1 methylation
level using clinical, pathologic and molecular variables.
We have found that the variability in LINE-1 methylation
levels remains even after accounting for clinical, patho-
logic and molecular variables, which indicates epige-
nomic diversity of colorectal cancers. We have also found
that LINE-1 extreme hypomethylators might constitute a
previously-unrecognized, distinct cancer subtype, which
may have substantial clinical implications with its young
age of onset and aggressive behavior [20].
Materials and methods
Study group
We utilized the databases of two large prospective cohort
studies, the Nurses' Health Study (N = 121,700 women
followed since 1976) [22], and the Health Professional
Follow-up Study (N = 51,529 men followed since 1986)
[22]. Data on height, weight, smoking status, and family
history of colorectal cancer in any first-degree relative
were obtained by biennial questionnaire. A subset of the
cohort participants developed colorectal cancers during
prospective follow-up. Previous studies on these cohort
studies have described baseline characteristics of partici-
pants and incident colorectal cancer cases, and con-
firmed that our colorectal cancers were well
representative as a population-based sample [22]. Data
on tumor location and stage were obtained through med-
ical record review. We collected paraffin-embedded tis-
sue blocks from hospitals where patients had undergone
resections of colorectal cancers. Based on availability of
adequate tissue specimens and results, a total of 869 col-
orectal cancers were included (Table 1). Among our
cohort studies, there was no significant difference in
demographic features between cases with tissue available
and those without available tissue [22]. This current anal-
ysis represents a new study using linear and logistic
regression models for LINE-1 methylation on the existing
colorectal cancer database (which has been previously
characterized for molecular features and clinical outcome
[19-24]), leading to the discovery of a possibly novel sub-
type of colorectal cancers. We comprehensively included
many of the previously characterized tumor markers [19-
24]), which have been linked to colorectal carcinogenesis.
In our previous studies which focused on different
hypotheses, we examined the relationship between LINE-
1 methylation and CpG island methylator phenotype
(CIMP) to test the hypothesis whether there is any rela-
tionship between global DNA methylation level and
CIMP [19]; the relation between LINE-1 methylation and
patient survival [20]; the relationship between LINE-1
methylation levels (as one of many molecular markers)
within synchronous colorectal cancer pairs [21]; and the
relationship between LINE-1 hypomethylation and 18 q
loss of heterozygosity (LOH) as a part of analysis on prog-
nostic significance of 18 q LOH [23]. Informed consent
was obtained from all study subjects. Tissue collection
and analyses were approved by the Harvard School of
Public Health and Brigham and Women's Hospital Insti-
tutional Review Boards.
Histopathologic evaluations
Hematoxylin and eosin (H&E) stained tissue sections
were examined by a pathologist (S.O.) unaware of other
data. The tumor grade was categorized as low (≥ 50%
gland formation) vs. high (< 50% gland formation) [25].
The presence/absence and extent of extracellular mucin
a n d  s i g n e t  r i n g  c e l l s  w e r e  r e c o r d e d  a s  p e r c e n t a g e  o f
mucinous and signet ring cell components, respectively
[25]. Each of Crohn's-like lymphocytic reaction, peritu-
moral lymphocytic reaction and tumor infiltrating lym-
phocytes (TIL) was recorded as either absent, mild,
moderate or severe [25].
DNA extraction and sodium bisulfite treatment
The methods for sodium bisulfite treatment of DNA have
previously been described [26]. H&E-stained slides of the
tumors were reviewed, and areas of tumor were marked,
to exclude pure normal tissue and enrich tumor DNA.
Tissue sections (depending on tissue and tumor size, in
average, large tumor tissue 10 μm × 1 section) from eachBaba et al. Molecular Cancer 2010, 9:125
http://www.molecular-cancer.com/content/9/1/125
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Table 1: LINE-1 methylation level in colorectal cancer.
Clinical, pathologic or molecular feature Total N Mean Standard deviation P value^
All cases 869 61.4 9.6
Sex 0.19
Men 394 (45%) 61.0 9.0
Women 475 (55%) 61.8 10.1
Age (years) 0.35
< 60 196 (23%) 60.5 10.5
60-69 363 (42%) 61.7 8.7
≥70 310 (36%) 61.5 9.9
Body mass index (BMI, kg/m2) 0.96
< 30 667 (83%) 61.3 9.5
≥30 141 (17%) 61.4 9.1
Family history of colorectal cancer 0.005
(-) 657 (76%) 61.9 9.6
(+) 212 (24%) 59.7 9.1
Smoking status 0.99
Never 350 (41%) 61.4 10.1
Past or current 508 (59%) 61.3 9.2
Tumor location 0.024
Proximal colon (cecum to transverse) 370 (44%) 61.9 9.2
Distal colon (splenic flexure to sigmoid) 274 (33%) 60.1 9.7
Rectum 192 (23%) 62.3 9.4
Disease stage 0.015
I 196 (25%) 61.5 9.2
II 253 (33%) 62.5 9.2
III 226 (29%) 60.1 9.5
IV 103 (13%) 60.0 11.0
Tumor grade 0.43
Low 777 (91%) 61.3 9.4
High 79 (9.2%) 62.3 11.2
Mucinous component 0.002
0% 554 (65%) 60.7 9.3
1-49% 188 (22%) 61.3 10.0
≥50% 115 (13%) 64.1 9.3
Signet ring cell component 0.009
0% 796 (93%) 61.0 9.4
1-49% 48 (5.6%) 63.5 10.8
≥50% 14 (1.6%) 67.6 8.5
Crohn's-like reaction 0.002
Absent/mild 684 (92%) 61.1 9.5
Moderate/severe 62 (8.3%) 65.2 9.6
Peritumoral lymphocytic reaction 0.018
Absent/mild 744 (89%) 60.9 9.4
Moderate/severe 93 (11%) 63.6 10.3
Tumor infiltrating lymphocytes (TIL) 0.043
Absent/mild 740 (89%) 60.9 9.5Baba et al. Molecular Cancer 2010, 9:125
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case were scraped off slides, suspended in 20 μl of the tis-
sue lysate (100 mmol/L Tris, pH 8, 10 mmol/L ethylene-
diaminetetraacetic acid, pH 8, 1 mg/ml proteinase K, and
0.05 mg/ml tRNA), and incubated at 50°C overnight. The
tissue lysate was then stored at -20°C until sodium
bisulfite treatment was performed. Sodium metabisulfite
(1.9 g) was dissolved in mixture of 3.2 ml of 0.44 mol/L
NaOH at 50°C. Then, 0.5 ml of 1 mol/L hydroquinone
was added to the dissolved sodium bisulfite mixture. An
18-μl aliquot of the tissue lysate was denatured at 100°C
for 10 minutes and chilled on ice. Then, 2 μl of 3 mol/L
NaOH was added and incubated at 42°C for 20 minutes.
Moderate/severe 96 (11%) 63.2 10.2
MSI status < 0.0001
MSI-low/MSS 728 (85%) 60.7 9.5
MSI-high 124 (15%) 64.7 8.9
CIMP status < 0.0001
CIMP-0 408 (47%) 60.2 9.8
CIMP-low 333 (38%) 61.3 9.3
CIMP-high 128 (15%) 65.1 8.3
CIN status (in MSI-low/MSS cases) 0.0002
(-) 142 (25%) 63.7 9.6
(+) 436 (75%) 60.3 9.0
KRAS mutation 0.90
(-) 538 (63%) 61.3 9.6
(+) 319 (37%) 61.2 9.4
BRAF mutation 0.001
(-) 728 (87%) 60.8 9.3
(+) 108 (13%) 64.2 10.2
PIK3CA mutation 0.24
(-) 646 (85%) 61.1 9.7
(+) 118 (15%) 62.2 9.3
TP53 expression 0.096
(-) 488 (57%) 61.8 9.8
(+) 371 (43%) 60.7 9.3
CDKN1A (p21) 0.0002
Lost 682 (81%) 60.6 9.6
Expressed 158 (19%) 63.7 9.0
CTNNB1 (β-catenin) score*  0.47
0-2 (inactive) 482 (64%) 61.4 9.8
3-5 (active) 273 (36%) 60.9 9.3
PTGS2 (COX-2) expression 0.98
(-) 142 (16%) 61.3 11.2
(+) 719 (84%) 61.3 9.2
FASN expression 0.16
(-) 742 (88%) 61.1 9.7
(+) 99 (12%) 62.4 8.7
^ P value was calculated by t-test assuming unequal variances (for binary variables) or ANOVA (analysis of variance; for 3-category variables). 
* CTNNB1 score was calculated as previously described [24].
There were cases with missing information in covariates. A p value for significance is adjusted to p = 0.0021 by Bonferroni correction for 
multiple hypothesis testing.
CIMP, CpG island methylator phenotype; MSI, microsatellite instability; MSS, microsatellite stable.
Table 1: LINE-1 methylation level in colorectal cancer. (Continued)Baba et al. Molecular Cancer 2010, 9:125
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The bisulfite solution (120 μl) was added (total volume of
140 μl) and incubated at 50°C for 15 hours in the dark.
The bisulfite-converted DNA was recovered using a Qia-
gen QIAamp viral RNA mini kit (Qiagen, Valencia, CA)
according to the manufacturer's instructions with some
modifications. Buffer AVL/carrier RNA (560 μl) was
added to the 140 μl of bisulfite-converted DNA sample
and incubated at room temperature for 10 minutes. Etha-
nol (560 μl) was then added, and after extensive mixing,
the mixture was loaded onto the provided spin columns
in consecutive 630-μl aliquots. After each loading, the
columns were centrifuged at full speed (21,000 × g) for 1
minute. Both the filtrate and spin column were saved, and
both filtrates were passed through the column a second
time in the same manner to increase the yield of recovery.
The spin column was then washed with 500 μl of buffer
AW1, followed by centrifugation at 21,000 × g for 1 min-
ute. Buffer AW2 (500 μl) was then added to the column,
and the column was centrifuged at 21,000 × g for 4 min-
utes to wash the column and eliminate possible buffer
AW2 carry over. DNA in the spin column was eluted by
the addition of 40 μl of buffer AVE, followed by a 1-min-
ute incubation at room temperature and centrifugation at
7600 × g for 1 minute. This elution step was repeated with
a second 40-μl volume of buffer AVE. Fifty μl of 0.2 mol/L
NaOH was added to the 80-μl pooled eluate for 15 min-
utes at room temperature to desulphonate the sample,
and then 10 μl of 1 mol/L HCl was added to for neutral-
ization. Buffer AVL/carrier RNA (560 μl) was then added
to the 140-μl sample mixture, and the recovery procedure
was repeated with a new spin column. The eluted DNA
(80-μl volume) was then used for Pyrosequencing analy-
sis and MethyLight analysis.
Real-time PCR (MethyLight) for quantitative DNA 
methylation analysis
Subsequent real-time PCR (MethyLight) [27] was vali-
dated and performed as previously described [26]. We
quantified DNA methylation in 8 CIMP-specific promot-
ers [CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1,
NEUROG1, RUNX3 and SOCS1] [28-30]. CIMP-high was
defined as the presence of ≥ 6 of 8 methylated promoters,
CIMP-low as the presence of 1/8-5/8 methylated promot-
ers, and CIMP-0 as the absence (0/8) of methylated pro-
moters, according to the previously established criteria
[30,31].
Pyrosequencing to Measure LINE-1 Methylation
In order to accurately quantify relatively high LINE-1
methylation levels, we utilized Pyrosequencing technol-
ogy (Figure 1) [10,19,32]. PCR and subsequent Pyrose-
quencing for LINE-1 were performed using the
PyroMark kit (Qiagen). This assay amplifies a region of
LINE-1 element (position 305 to 331 in accession No.
X58075), which includes 4 CpG cites. The PCR condition
was 45 cycles of 95°C for 20 sec, 50°C for 20 sec and 72°C
for 20 sec, followed by 72°C for 5 min. The biotinylated
PCR product was purified and made single-stranded to
act as a template in a pyrosequencing reaction, using the
Pyrosequencing Vacuum Prep Tool (Qiagen). Pyrose-
quencing reactions were performed in the PSQ HS 96
System (Qiagen). The nucleotide dispensation order was:
ACT CAG TGT GTC AGT CAG TTA GTC TG. The
non-CpG cytosine in LINE-1 repetitive sequences has
been documented to be rarely methylated [33]. Thus,
complete conversion of cytosine at a non-CpG site
ensured successful bisulfite conversion. The amount of C
relative to the sum of the amounts of C and T at each
CpG site was calculated as percentage (i.e., 0 to 100). The
average of the relative amounts of C in the 4 CpG sites
was used as overall LINE-1 methylation level in a given
tumor. LINE-1 methylation level measured by Pyrose-
quencing is a good indicator of cellular 5-methylcytosine
level (i.e., global DNA methylation level) [10,18]. We
compared results from cancer cells collected by laser cap-
ture microdissection (LCM) with results from cancer tis-
sues dissected manually using HE sections with marking
for tumor areas [32]. We showed that DNA hypomethyla-
tion could be measured in manually dissected cancer tis-
sue without LCM, and that precision of measurement in
manually dissected cancer tissue was superior to cancer
cells collected by LCM [32]. In addition, to extensively
validate LINE-1 methylation Pyrosequencing assay, we
performed bisulfite conversion on seven different DNA
specimen aliquots and repeated PCR-Pyrosequencing
seven times using 10 macro-dissected colorectal cancers.
Bisulfite-to-bisulfite (between-bisulfite treatment) stan-
dard deviation ranged from 0.4-2.4 (median, 1.2), and
run-to-run (between-PCR Pyrosequencing run) standard
deviation ranged from 1.3-4.4 (median, 3.0) [32]. More-
over, intraclass correlation coefficient (ICC) of LINE-1
methylation in cancer tissues was 0.77, which suggests
good reliability in the measurement.
Sequencing of KRAS, BRAF and PIK3CA, and analyses for 
microsatellite instability (MSI) and chromosomal instability 
(CIN)
PCR and Pyrosequencing targeted for KRAS (codons 12
and 13) [34], BRAF (codon 600) [35] and PIK3CA (exons
9 and 20) [36,37] were performed as previously described.
MSI analysis was performed, using D2S123, D5S346,
D17S250, BAT25, BAT26, BAT40, D18S55, D18S56,
D18S67 and D18S487 [38]. MSI-high was defined as the
presence of instability in ≥30% of the markers, and MSI-
low/microsatellite stability (MSS) as the presence of 0-
29% unstable markers. Loss of heterozygosity (LOH)
analysis was performed using microsatellite markers
(D2S123, D5S346, D17S250, D18S55, D18S56, D18S67Baba et al. Molecular Cancer 2010, 9:125
http://www.molecular-cancer.com/content/9/1/125
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and D18S487). LOH at each locus was defined as ≥40%
reduction of one of two allele peaks in tumor DNA rela-
tive to normal DNA. CIN positivity was defined as the
presence of LOH in any of the chromosomal segments
among 2 p, 5 q, 17 q and 18 q, and CIN negativity was
defined as the absence of LOH in any of the chromosomal
segments with the presence of at least two informative
segments [39,40].
Immunohistochemistry for TP53, CDKN1A, CTNNB1, PTGS2 
and FASN
Tissue microarrays (TMA) were constructed as previ-
ously described [41]. Methods of immunohistochemistry
were previously described for TP53 (p53) [42], CDKN1A
(p21) [43,44]; CTNNB1 (β-catenin) [24]; PTGS2
(cyclooxygenase-2; COX-2) [22,38] and FASN [38,45]
(Additional file 1 for the method summary). The
CTNNB1 score (i.e., a summation of membrane loss, and
cytoplasmic and nuclear localization) used in this current
study has been used as a surrogate of CTNNB1 activation
caused not only by APC loss but also by other mecha-
nisms, including APC mutation, APC methylation, and
CTNNB1 mutation [46]. Appropriate positive and nega-
tive controls were included in each run of immunohis-
tochemistry. Each immunohistochemical maker was
interpreted by one of the investigators (TP53, CDKN1A,
PTGS2 and FASN by S.O.; CTNNB1 by K.N.) unaware of
other data. A random selection of 108-179 cases was
examined for each marker by a second observer (TP53
and FASN by K.N.; CDKN1A by K.S.; CTNNB1 by S.O.;
PTGS2 by R. Dehari, Kanagawa Cancer Center) unaware
of other data. The κ coefficients between the two observ-
ers were 0.65 for CTNNB1 (N = 142), 0.62 for CDKN1A
(N = 179), 0.75 for TP53 (N = 118), 0.57 for FASN (N =
146) and 0.62 for PTGS2 (N = 108) (all p < 0.0001), indi-
cating good to substantial agreement.
Figure 1 Pyrosequencing to measure LINE-1 methylation. A. LINE-1 hypermethylated tumor. B. LINE-1 hypomethylated tumor. The % numbers 
(in blue shade) are proportions of C and T at each CpG site after bisulfite conversion, and the methylation level of each CpG site is estimated by the 
proportion of C (%). An overall LINE-1 methylation level is calculated as the average of the proportions of C (%) at the 4 CpG sites. The first, third and 
fourth CpG sites follow mononucleotide T repeats, resulting in higher T peaks (in yellow shade) than the second CpG site, and the proportion of C (%) 
has been adjusted accordingly. The arrows indicate no residual C at the non-CpG site, ensuring complete bisulfite conversion.
Not CpG
Not CpG
A
B
LINE-1 methylation level, 70.5
LINE-1 methylation level, 47.1Baba et al. Molecular Cancer 2010, 9:125
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Statistical analysis
We used the SAS program (Version 9.1, SAS Institute,
Cary, NC) for all statistical analyses. All p values were
t w o - s i d e d .  B e c a u s e  o f  m u l t i p l e  h y p o t h e s i s  t e s t i n g ,  a  p
value for significance was adjusted by Bonferroni correc-
tion to p = 0.0021 (= 0.05/24). To compare mean LINE-1
methylation levels, we performed the t-test assuming
unequal variances or ANOVA for variables with more
than 2 categories. Pearson correlation test was used to
assess correlations of LINE-1 methylation with raw con-
tinuous values of age, body mass index (BMI), percentage
of mucinous component and percentage of signet ring
cell component. Fisher's exact test was used to assess
associations between categorical variables.
We constructed a multivariate linear regression model
to assess whether clinical, pathologic and molecular vari-
ables could predict LINE-1 methylation level in 869 col-
orectal cancers. Variables initially included sex, age
(continuous), BMI (continuous), smoking status (continu-
ous pack-years), family history of colorectal cancer in any
first degree relative (present vs. absent), tumor location
(proximal colon vs. distal colon vs. rectum), disease stage
(I vs. II vs. III vs. IV vs. unknown), tumor grade (low vs.
high), mucinous component (%, continuous), signet ring
cell component (%, continuous), Crohn's-like reaction
(ordinal scale 1-4), peritumoral lymphocytic reaction
(ordinal scale 1-4), tumor infiltrating lymphocytes (ordi-
nal scale 1-4), CTNNB1 score (ordinal scale 1-5), CIMP
status (high vs. low/0), MSI status (high vs. low/MSS),
BRAF  (mutant vs. wild-type), KRAS  (mutant vs. wild-
type), PIK3CA (mutant vs. wild-type), TP53 (positive vs.
negative), CDKN1A (expressed vs. lost), PTGS2 (positive
vs. negative), and FASN (positive vs. negative). Cases with
missing data in a categorical or ordinal variable were
included in a majority (or the most common) category;
such variables included BMI (7.0%), tumor location
(3.8%), stage (10%), grade (1.5%), mucinous component
(1.4%), signet ring cell component (1.3%), peritumoral
lymphocytic reaction (3.7%), TIL (3.8%), MSI (2.2%),
KRAS (1.4%), BRAF (3.8%), PIK3CA (12%), TP53 (1.2%),
CDKN1A (3.4%), CTNNB1 (13%), PTGS2 (0.9%) and
FASN (3.2%). We performed multivariate linear regres-
sion analysis with a backward stepwise elimination proce-
dure to limit the variables with p ≤ 0.20. After the final
multivariate linear regression model was constructed, a
distribution of residuals (observed LINE-1 methylation
level minus predicted LINE-1 methylation level by the
regression model) was visually inspected and confirmed
that the assumptions of residuals' normality and equal
variance across LINE-1 methylation level were generally
satisfied. We assessed whether there were any individu-
ally influential outliers by residual plots and Cook's D sta-
tistics (a summary measure of influence) and found that
there were no significant outliers (Cook's D value < 0.035
for all cases). This indicates that our overall findings were
not influenced by any particular outlier subjects.
We assessed potential non-linearity of continuous and
ordinal variables (age, BMI, smoking status, disease stage,
mucinous component, signet ring cell component,
Crohn's-like reaction, peritumoral lymphocytic reaction,
tumor infiltrating lymphocytes and CTNNB1 score) by
constructing a squared term for each of these variables
(excluding data-missing cases) and included these with
the original variables in an additional multivariate model.
As a result, no squared term showed significant relation-
ship with LINE-1 methylation (all p > 0.20).
In addition, we constructed a multivariate logistic
regression model for the binary LINE-1 outcome (cutoff
at 40, 50 or 60) using the same set of covariates as in the
final linear regression model. The logistic regression
model formula yielded a score for each case based on β
coefficients and a combination of covariate status. We
drew ROC (receiver operator characteristics) curves for
the diagnosis of LINE-1 hypomethylation as the binary
outcome, using different thresholds of the regression
score for test positivity. ROC curves for each cutoff was
averaged over 10 folds each using 25% randomly heldout
test data for cross validation. Area under the curve (AUC)
value of an averaged ROC curve reflected an ability of a
regression model to diagnose binary LINE-1 hypomethy-
lation.
Results
LINE-1 methylation levels in 869 colorectal cancers
Utilizing 869 colorectal cancers identified in the two
independent prospective cohort studies, we quantified
LINE-1 methylation by bisulfite-PCR and Pyrosequenc-
ing technology (Figure 1). LINE-1 methylation is a good
indicator of cellular methylcytosine level (i.e., global DNA
methylation level) [10-12], and the Pyrosequencing assay
described here can provide precise data for LINE-1 meth-
ylation levels [10,12,18,32]. Using the 4 CpG sites in
LINE-1, we calculated the average of the percentage
numbers (at the 4 CpG sites) of C (methylated) allele
among C (methylated) and T (unmethylated) alleles and
used this as the LINE-1 methylation level in a given
tumor (described as 0 to 100). We previously examined
LINE-1 methylation levels in normal colonic mucosa
adjacent to colorectal cancers as well as peripheral blood
cells from normal individuals, and found that LINE-1
methylation levels in those specimens were high (> 65)
[21,32]. In addition, we previously showed that DNA
hypomethylation could be precisely measured in manu-
ally dissected cancer tissue, and that precision of LINE-1
methylation measurement in manually dissected cancer
tissue was superior to LINE-1 methylation measurement
in cancer cells collected by laser capture microdissection
(LCM) [32]. Because a manual dissection procedureBaba et al. Molecular Cancer 2010, 9:125
http://www.molecular-cancer.com/content/9/1/125
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could be easily implemented in this large-scale study and
a large amount of DNA could be obtained for better pre-
cision, we used manual dissection to obtain DNA from
the 869 tumors.
LINE-1 methylation levels in the 869 tumors (Figure 2)
widely distributed (ranging from 23.1 to 90.3 of 0-100
scale; median 62.3; mean 61.4; interquartile range 12.5)
and fell into two apparent classes: 22 extreme hypometh-
ylators below a methylation level of 40, and 847 remain-
ing tumors with normally distributed LINE-1
methylation levels (Shapiro-Wilk p > 0.20 for a deviation
of normality). We have shown that between-assay varia-
tion of LINE-1 methylation levels in repeated measure-
ments is small and coefficient of variation (CV) is 4-5%
[32]; this argues against attributing the large variation in
LINE-1 methylation observed between tumors to a labo-
ratory measurement error. In combination with the
highly significant association between LINE-1 hypom-
ethylation and patient mortality [20], this indicates that
variation in LINE-1 methylation is likely intrinsic to the
biology of individual tumors.
LINE-1 methylation and clinical, pathologic and molecular 
variables
We examined LINE-1 methylation level in colorectal can-
cer according to various clinical, pathologic or molecular
feature (Table 1). In univariate analysis (with Bonferroni-
corrected significance level at p = 0.05/24 = 0.0021),
LINE-1 methylation was significantly related with muci-
nous component (p = 0.002), Crohn's-like reaction (p =
0.002), microsatellite instability (MSI, p < 0.0001), CpG
island methylator phenotype (CIMP, p < 0.0001), chro-
mosomal instability (CIN) in MSI-low/MSS cases (p =
0.0002), BRAF mutation (p = 0.001) and CDKN1A (p21)
expression (p = 0.0002).
We also examined correlations of LINE-1 methylation
with raw values for age, body mass index (BMI), percent-
age of mucinous component and percentage of signet
ring cell component. In all cases, the Pearson correlation
coefficient was between 0 and 0.164 (i.e., all R2 < 0.027),
indicating that none of these variables alone could
explain substantial variability of LINE-1 methylation.
Multivariate linear regression analysis for tumoral LINE-1 
methylation level
We constructed a multivariate linear regression model
for LINE-1 methylation level as an outcome variable,
using clinical, pathologic and other molecular variables.
A model that could predict LINE-1 methylation level
might be useful, considering the importance of LINE-1
hypomethylation as a highly significant prognostic bio-
marker in colon cancer [20]. Variables in the multivariate
linear regression model initially included sex, age, BMI,
family history of colorectal cancer, smoking status, dis-
ease stage tumor location, grade, mucinous component,
signet ring cells, Crohn's-like reaction, peritumoral lym-
phocytic reaction, tumor infiltrating lymphocytes (TIL),
CIMP, MSI, BRAF  mutation,  KRAS mutation,  PIK3CA
mutation, TP53 expression, CDKN1A expression,
CTNNB1 score, PTGS2 expression, and FASN expres-
sion. We excluded CIN status from our list of covariates
because global DNA hypomethylation might be a cause
of CIN. Thus, in a linear regression model to predict
LINE-1 methylation level (as an outcome variable), a
putative consequential variable (such as CIN) should not
be put as a predictor variable. After a backward stepwise
elimination to avoid overfitting, the variables listed in
Table 2 remained in the final model. Importantly, the R-
square of the final multivariate model was only 0.084,
indicating that 92% of the LINE-1 methylation variability
still remained.
To validate the multivariate linear regression model, we
examined the residuals (i.e., observed LINE-1 methyla-
tion level minus predicted LINE-1 methylation level by
the regression model) (Figure 3). Across all predicted
LINE-1 methylation levels, the distribution of residuals
was approximately normal and homoscedastic. These
results suggested that the multivariate linear regression
model was in general appropriately constructed. Of note,
there was a cluster of tumors which were separate from
the normal and homoscedastic distribution around the 0
residual line. These tumors greatly overlapped with
LINE-1 extreme hypomethylators (LINE-1 methylation
level < 40).
All variables included in the final multivariate linear
regression model are listed in Table 2. The adjusted β
coefficient represented an increase in LINE-1 methyla-
Figure 2 Distribution of LINE-1 methylation levels in 869 colorec-
tal cancers. LINE-1 methylation levels distributed approximately nor-
mally, except for the presence of extreme hypomethylators (LINE-1 
methylation value < 40), which appear to be separate from the remain-
ing normal distribution.
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tion level by a given variable, assuming that all other vari-
ables remained constant. The most significant predictor
was CIMP-high [vs. CIMP-0; adjusted β coefficient 4.79;
95% confidence interval (CI), 2.69 to 6.89; p < 0.0001], fol-
lowed by signet ring cells (for 10% increase; adjusted β
coefficient 1.15; 95% CI, 0.53 to 1.77; p = 0.0003). Based
on the conservative significance level at p = 0.0021 by
Bonferroni correction for multiple hypothesis testing, no
other variables showed robustly significant association,
although major indicators including family history, tumor
location, and stage showed nominal significance (insuffi-
cient to contribute significantly to model accuracy; see
Figure 4). All other variables were not significantly asso-
ciated with LINE-1 methylation.
To eliminate potential confounding effect of HNPCC
(hereditary nonpolyposis colorectal cancer), we identified
19 possible or suspected HNPCC cases [i.e., MSI-high
CIMP-low/0 tumors (none of which turned out to be
BRAF-mutated) with any of the followings: (1) positive
family history of colorectal cancer in at least one first-
degree relative; (2) loss of MLH1 without evidence of
MLH1 methylation; (3) loss of PMS2 without evidence of
MLH1 loss; (4) loss of MSH2 and/or MSH6]. After we
excluded these 19 cases, multivariate linear regression
analysis showed very similar results (data not shown).
ROC curves for binary LINE-1 methylation outcome in 
logistic regression analysis
We constructed multivariate logistic regression models
for binary LINE-1 outcomes using different cutoffs (40,
50 and 60) with the same set of covariates as in the final
linear regression model. The logistic regression model
formula yielded a score for each case based on β coeffi-
cients and a combination of covariate status. We drew
ROC (receiver operator characteristics) curves for the
diagnosis of LINE-1 hypomethylation as a binary out-
come, using different thresholds of the regression score
for test positivity (Figure 4). Area under the curve (AUC)
remained relatively low (< 0.63) for LINE-1 hypomethyla-
tion at a cutoff of < 40, < 50 or < 60 LINE-1 methylation.
These results also support our finding that LINE-1 meth-
ylation status was not well predicted by these variables.
Table 2: Multivariate linear regression analysis to predict LINE-1 methylation level in 869 colorectal cancers
Variables in the final model Adjusted β coefficient (change in LINE-1 
methylation level by a given variable)
95% confidence limits P value (partial F-test)
CIMP status < 0.0001
CIMP-high (vs. CIMP-0) 4.79 2.69, 6.89 < 0.0001 (T test)
CIMP-low (vs. CIMP-0) 1.17 -0.18, 2.52 0.090 (T test)
Signet ring cell component (for 10% 
increase)
1.15 0.53, 1.77 0.0003
Rectal location (vs. colon) 2.22 0.68, 3.75 0.0046
Family history of colorectal cancer (present 
vs. absent)
-1.92 -3.36, -0.48 0.0089
Disease stage (for one unit increase in 
ordinal scale, I-IV)
-0.83 -1.50, -0.16 0.016
CDKN1A (p21) loss (vs. expression) -2.06 -3.75, -0.37 0.017
Crohn's-like reaction [for one unit increase in 
ordinal scale 1 (absent)-4 (strong)]
1.26 -0.20, 2.31 0.020
High tumor grade (vs. low grade) -2.47 -5.00, 0.07 0.056
Male (vs. female) 1.03 -0.24, 2.29 0.11
Body mass index (BMI, for an increase of 5 
kg/m2)
0.50 -0.18, 1.18 0.15
The multivariate linear regression model initially included the variables listed in the table, age, smoking, mucinous component, peritumoral 
lymphocytic reaction, tumor infiltrating lymphocytes, CTNNB1 score, MSI status, mutations in BRAF, KRAS and PIK3CA, and expression status of 
TP53, CDKN1A (p21), PTGS2 (cyclooxygenase-2), and FASN. A backward elimination with a threshold of p = 0.20 was performed to select variables 
in the final model. The adjusted β coefficient represents a change (increase or decrease) in LINE-1 methylation level by a given variable, assuming 
that all other variables remain constant. R-square of the multivariate model was only 0.084, indicating that 92% of variability in LINE-1 
methylation levels remained unexplained by this model. A p value for significance is adjusted to p = 0.0021 by Bonferroni correction for multiple 
hypothesis testing.
CIMP, CpG island methylator phenotype; MSI, microsatellite instability.Baba et al. Molecular Cancer 2010, 9:125
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LINE-1 extreme hypomethylated tumors
We examined clinical, pathologic and molecular features
of tumors with LINE-1 methylation value below 40,
because both the overall distribution of LINE-1 methyla-
tion levels (Figure 2) and the residuals plot of the linear
regression model (Figure 3) indicated the presence of a
distinct group of LINE-1 extreme hypomethylators.
Notably, there was a relationship between LINE-1
extreme hypomethylation and younger age at diagnosis;
45% (10/22) of cases with LINE-1 methylation < 40 were
less than 60 years old, while only 22% (186/847) of the
remaining patients were less than 60 years old (p =
0.0058) (Table 3). Overall distribution of age in these
LINE-1 < 40 hypomethylators was somewhat bimodal
with fewer cases (14% = 3/22) being 60-69 years old, com-
pared to the remaining patients (with LINE-1 methyla-
tion ≥ 40) where 43% (360/847) of patients were 60-69
years old. While the total number of LINE-1 < 40 hypom-
ethylators (N = 22) was not enough to achieve statistical
significance after Bonferroni correction, this difference in
age distribution further supports the presence of a dis-
tinct group of LINE-1 extreme hypomethylators. These
LINE-1 extreme hypomethylators might arise through a
different carcinogenic pathway, resulting in a younger age
of onset and more aggressive tumor behavior [20].
Discussion
In this study, we examined whether clinical, pathologic
and molecular variables could potentially explain the
wide population variability of LINE-1 methylation in col-
orectal cancer. Global DNA hypomethylation has been
associated with genomic instability, and implicated in the
development of various human cancers [3-7,47-52]. To
estimate global DNA methylation level, we measured
tumor LINE-1 methylation, which has been correlated
well with cellular 5-methylcytosine level (i.e., global DNA
methylation level) in cancer tissues [10-12]. This is not
surprising because LINE-1 retrotransposon constitutes a
substantial portion (~17%) of the entire human genome
[9]. LINE-1 methylation in colorectal cancer is highly
variable [18,19], and is strongly associated with survival
among colon cancer patients [20]. Therefore, accurate
prediction of tumoral LINE-1 methylation level from
clinical and pathological features, if possible, may be clin-
ically useful. Furthermore, recent evidence suggests a
non-stochastic component of variable LINE-1 methyla-
tion levels in synchronous colorectal cancers (i.e., two or
more primary tumors in one individual) [21]. Thus, it is
of particular interest to identify clinical, environmental or
tumoral factors, if any, which influence LINE-1 methyla-
tion in colorectal cancer [53].
Although accumulating evidence has suggested global
DNA hypomethylation in human cancers, the mecha-
nisms eliciting this alteration are still unknown. Possible
mechanisms include inadequate expression or regulation
of DNA methyltransferases, insufficient levels of methyl
group donors (i.e., disorder of one-carbon metabolism
pathway), aberrant activation of DNA demethylases, and
altered expression of chromatin regulators directing
DNA methyltransferases [54-56]. The mechanism by
which global DNA hypomethylation may confer a poor
prognosis (i.e., tumor progression) also remains specula-
tive. Genome-wide DNA hypomethylation has been asso-
ciated with genomic instability [5], which may confer
poor prognosis. Transcriptional dysregulation might be
another possible mechanism, and activation of proto-
oncogenes, endogenous retroviruses, or transposable ele-
ments might affect tumor aggressiveness. A third possible
mechanism involves inflammatory mediators and tumor
hypoxia; the latter has been associated with genomic
DNA hypomethylation [57]. Activation of hypoxia-induc-
ible factor HIF1A has been associated with poor progno-
sis in colon cancer [58]. A better understanding of
relationship between LINE-1 hypomethylation and clini-
cal, pathologic, or molecular feature may shed lights on
these biological mechanisms of LINE-1 hypomethylation
in human cancer.
The efficiency and precision of bisulfite conversion is
very crucial for quantitative assays based on sodium
bisulfite treatment of genomic DNA. As the non-CpG
cytosine in LINE-1 repetitive sequences has been docu-
mented to be rarely methylated [33], we used the non-
CpG cytosine as a built-in control for bisulfite conversion
efficiency and confirmed successful bisulfite conversion
Figure 3 Residuals plot of multivariate linear regression model to 
predict LINE-1 methylation in 869 colorectal cancers. Each dot rep-
resents each case. The x axis represents LINE-1 methylation level pre-
dicted by the regression model, and the y axis represents the residuals 
(observed LINE-1 methylation level minus predicted LINE-1 methyla-
tion level by the regression model). A distribution of the residuals is ap-
proximately normal across predicted LINE-1 methylation levels, except 
for the presence of outliers (arrow). The arrow suggests the presence 
of a distinct group of tumors, separate from the normal and homosce-
dastic distribution around the 0 residual line.
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by complete conversion of this cytosine (Figure 1,
arrows). In addition, we have previously assessed preci-
sion of bisulfite treatment and precision of subsequent
Pyrosequencing assay to measure LINE-1 methylation in
paraffin-embedded colon cancers [32]. We assessed pre-
cision of bisulfite conversion by repeating bisulfite treat-
ment. Basically, we performed bisulfite conversion on
seven different DNA specimen aliquots from each of 10
different colorectal cancers. Bisulfite-to-bisulfite
(between-bisulfite treatment) standard deviation ranged
from 0.4-2.4 (median, 1.2), indicating good precision of
bisulfite conversion in terms of LINE-1 methylation mea-
surement.
We have discovered the relationship between LINE-1
extreme hypomethylation (< 40) and younger age of onset
(< 60 year old). The LINE-1 extreme hypomethylators
appear to be separate from the normal distribution of
LINE-1 methylation observed in the remaining majority
of colorectal cancers. This group of colorectal cancers has
not been described previously, because it is necessary to
analyze a large number of molecularly and clinically-
annotated colorectal cancers with precise LINE-1 methy-
lation data. The relationship of LINE-1 extreme hypom-
ethylation with earlier age of onset and poor prognosis
[20] support the presence of a distinct subtype of colorec-
tal cancers with a unique pathogenic mechanism. None-
theless, additional studies are necessary to confirm our
findings. We are currently investigating whether this class
of LINE-1 extreme hypomethylators may indeed be
driven by different underlying molecular mechanisms
than those inducing the normal distribution of LINE-1
methylation seen in the majority of colorectal cancers.
W e have also found that the linear regression model
explains only 8.4% of variability of LINE-1 methylation,
and the 92% of the variability still remained unexplained.
In addition, we have shown that multivariate logistic
regression models do not significantly predict binary
LINE-1 methylation outcomes. Our results imply that
Figure 4 ROC (receiver operator characteristics) curves for the diagnosis of LINE-1 hypomethylation as a binary outcome using different 
cutoffs (40, 50 and 60 of 0-100 scale). Multivariate logistic regression models for the binary LINE-1 methylation outcomes were constructed using 
the same set of covariates as in the linear regression model. ROC curves for each cutoff was averaged over 10 folds each using 25% randomly heldout 
test data for cross validation. Area under the curve (AUC) represents performance characteristics of the multivariate model as a clinical test for the 
specific binary outcome.
Figure 4Baba et al. Molecular Cancer 2010, 9:125
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Table 3: LINE-1 extreme hypomethylators (< 40) compared to colorectal cancers with LINE-1 methylation level ≥40.
Clinical, pathologic or molecular feature Total N LINE-1 methylation level P value^
≥40 < 40
All cases 869 847 22
Sex 1.00
Men 394 (45%) 384 (45%) 10 (45%)
Women 475 (55%) 463 (55%) 12 (55%)
Age (years) 0.0058
< 60 196 (23%) 186 (22%) 10 (45%)
60-69 363 (42%) 360 (43%) 3 (14%)
≥70 310 (36%) 301 (36%) 9 (41%)
Body mass index (BMI, kg/m2) 1.00
< 30 667 (83%) 649 (82%) 18 (86%)
≥30 141 (17%) 138 (18%) 3 (14%)
Family history of colorectal cancer 0.80
(-) 657 (76%) 641 (76%) 16 (73%)
(+) 212 (24%) 206 (24%) 6 (27%)
Smoking status 0.082
Never 349 (41%) 336 (40%) 13 (59%)
Past or current 508 (59%) 499 (60%) 9 (41%)
Tumor location 0.094
Proximal colon (cecum to transverse) 370 (44%) 365 (45%) 5 (25%)
Distal colon (splenic flexure to sigmoid) 274 (33%) 263 (32%) 11 (55%)
Rectum 192 (23%) 188 (23%) 4 (20%)
Disease stage 0.66
I 196 (25%) 193 (25%) 3 (14%)
II 253 (33%) 246 (32%) 7 (33%)
III 226 (29%) 218 (29%) 8 (38%)
IV 103 (13%) 100 (13%) 3 (14%)
Tumor grade 0.45
Low 777 (91%) 758 (91%) 19 (86%)
High 79 (9.2%) 76 (9.1%) 3 (14%)
Mucinous component 0.53
0% 554 (65%) 541 (65%) 13 (59%)
1-49% 188 (22%) 181 (22%) 7 (32%)
≥50% 115 (13%) 113 (14%) 2 (9.1%)
Signet ring cell component 1.00
0% 796 (93%) 775 (93%) 21 (95%)
1-49% 48 (5.6%) 47 (5.6%) 1 (4.5%)
≥50% 14 (1.6%) 14 (1.7%) 0
Crohn's-like reaction 1.00
Absent/mild 584 (90%) 571 (90%) 13 (93%)
Moderate/severe 62 (9.6%) 61 (9.7%) 1 (7.1%)
Peritumoral lymphocytic reaction 0.73
Absent/mild 744 (89%) 725 (89%) 19 (86%)Baba et al. Molecular Cancer 2010, 9:125
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Moderate/severe 93 (11%) 90 (11%) 3 (14%)
Tumor infiltrating lymphocytes (TIL) 0.73
Absent/mild 740 (89%) 721 (89%) 19 (86%)
Moderate/severe 96 (11%) 93 (11%) 3 (14%)
MSI status 0.76
MSI-low/MSS 728 (85%) 709 (85%) 19 (90%)
MSI-high 124 (15%) 122 (15%) 2 (9.5%)
CIMP status 0.14
CIMP-0 408 (47%) 393 (46%) 15 (68%)
CIMP-low 333 (38%) 327 (39%) 6 (27%)
CIMP-high 128 (15%) 127 (15%) 1 (4.6%)
KRAS mutation 0.38
(-) 538 (63%) 522 (63%) 16 (73%)
(+) 319 (37%) 313 (37%) 6 (27%)
BRAF mutation 1.00
(-) 728 (87%) 709 (87%) 19 (90%)
(+) 108 (13%) 106 (13%) 2 (9.5%)
PIK3CA mutation 0.76
(-) 646 (85%) 627 (84%) 19 (90%)
(+) 118 (15%) 116 (16%) 2 (9.5%)
TP53 expression 0.19
(-) 488 (57%) 472 (56%) 16 (73%)
(+) 371 (43%) 365 (44%) 6 (27%)
CDKN1A 0.099
Lost 682 (81%) 661 (81%) 21 (95%)
Expressed 158 (19%) 157 (19%) 1 (4.6%)
CTNNB1 score*  1.00
0-2 (inactive) 482 (64%) 470 (64%) 12 (63%)
3-5 (active) 273 (36%) 266 (36%) 7 (37%)
PTGS2 expression 0.073
(-) 142 (16%) 135 (16%) 7 (32%)
(+) 719 (84%) 704 (84%) 15 (68%)
FASN expression 0.50
(-) 742 (88%) 721 (88%) 21 (95%)
(+) 99 (12%) 98 (12%) 1 (4.6%)
(%) indicates the proportion of cases with a specific clinical, pathologic or molecular feature among tumors with LINE-1 methylation level ≥ 
40 [or tumors with LINE-1 methylation level < 40]. A p value for significance is adjusted to p = 0.0021 by Bonferroni correction for multiple 
hypothesis testing.
^ p values were based on Fisher's exact test.
* CTNNB1 score was calculated as previously described [24].
CIMP, CpG island methylator phenotype; MSI, microsatellite instability; MSS, microsatellite stable.
Table 3: LINE-1 extreme hypomethylators (< 40) compared to colorectal cancers with LINE-1 methylation level ≥40. (Continued)
LINE-1 methylation in colorectal cancer can vary greatly
even after accounting for the clinical, pathologic and
molecular features (examined in this study), despite the
uniformity within individual patients in cases of synchro-
nous colorectal cancers [21]. Our data could point to sev-
eral interesting potential hypotheses for underlying
biological mechanisms; First, genomic methylation levels
and tumor progression could be co-influenced by a vari-
ety of environmental factors (e.g., smoking, alcohol, or
dietary pattern) for each patient. Second, a stochastic ele-Baba et al. Molecular Cancer 2010, 9:125
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m e n t  i n  t h e  u n d e r l y i n g  r e g u l a t o r y  n e t w o r k  c o u l d  b e
improperly downregulated according to genomic DNA
methylation status. Third, specific genes responsible for
tumor behavior (e.g., tumor progression) might be aber-
rantly regulated in cases of extreme hypomethylation. We
await further studies to elucidate the exact mechanisms
of LINE-1 hypomethylation in colorectal cancers.
Examination of epigenetic and genetic aberrations is
important in cancer research [59-64]. We utilized a quan-
titative Pyrosequencing assay for LINE-1 methylation,
which is robust and can accurately quantify LINE-1
methylation level [10,12]. Pyrosequencing technology
can detect subtle differences in average LINE-1 methyla-
tion levels among different colon cancer subtypes [e.g.,
microsatellite instability (MSI)-high vs. microsatellite sta-
ble (MSS)] [18,19], emphasizing the importance of the
use of an accurate and precise method to measure LINE-
1 methylation. Our previous survival data indicates that
LINE-1 measurement by Pyrosequencing is highly signif-
icantly associated with patient outcome [20]. Considering
the high reproducibility of LINE-1 Pyrosequencing
[10,12,32], the large variation in LINE-1 methylation lev-
els likely reflects true heterogeneity in global methylation
levels among individual tumors. Inter-tumoral biological
heterogeneity reflecting the LINE-1 methylation varia-
tion is also supported by the highly significant association
between LINE-1 methylation level and patient survival
[20].
Molecular classification of colorectal cancer based on
MSI and the CpG island methylator phenotype (CIMP)
status is increasingly important, because MSI and CIMP
status reflect global genomic and epigenomic aberrations
in tumor cells. Both CIMP-high and MSI-high are
inversely associated with LINE-1 hypomethylation, sug-
gesting that CIMP/MSI and genomic hypomethylation
may represent different pathways to colorectal cancer. In
addition, in non-MSI-high tumors, chromosomal insta-
bility (CIN) is correlated with LINE-1 hypomethylation,
supporting the possible link between genome-wide
hypomethylation and CIN. Further studies are necessary
to examine the exact mechanism of how genomic hypom-
ethylation, CIMP, MSI and CIN interact in colorectal
cancer development and contribute to colorectal cancer
progression.
In the multivariate linear and logistic regression mod-
els, we included key molecular events that have been well
documented in colorectal cancer [65-68]. Those molecu-
lar features include CIMP, MSI and TP53, all of which are
related with LINE-1 or global DNA hypomethylation [4-
7,18,19,49,50]. In addition, our tumor database has
enabled us to include other molecular variables (such as
CDKN1A expression, CTNNB1 score, PTGS2 expres-
sion, FASN expression, KRAS mutation, BRAF mutation
and  PIK3CA  mutation, all of which have been related
wit h MS I or  CIMP ),  as  we ll  as c l inica l a nd pa t hol ogic
variables. Therefore, our multivariate linear and logistic
regression analysis was quite comprehensive.
Although the multivariate linear regression model can-
not explain a wide variation of tumoral LINE-1 methyla-
tion, the model can provide us with useful information on
the independent relations of LINE-1 methylation with
various clinical, pathologic and molecular features of col-
orectal cancer. The possible relationship of LINE-1 meth-
ylation with signet ring cell component (p = 0.0003) and
rectal location (vs. colon; p = 0.0046) are intriguing. The
mechanism of this relation remains to be investigated. In
contrast, we found no significant difference in LINE-1
methylation between right colon and left colon, which is
in agreement with data on LINE-1 methylation in normal
colonic mucosa [52,53]. The relation between family his-
tory of colorectal cancer and LINE-1 hypomethylation (p
= 0.0089) may imply the presence of genetic component
in global DNA hypomethylation. Of note, we have previ-
ously reported that certain SNPs in one-carbon metabo-
lism genes are not associated with LINE-1
hypomethylation [69]. Nonetheless, any of associations
with p > 0.0021 in this current study could be a chance
finding due to multiple hypothesis testing. Additional
independent studies are necessary to confirm these asso-
ciations.
Conclusions
In this study utilizing large database of 869 colorectal
cancers, we have shown three main findings; first, LINE-1
extreme hypomethylators skew a distribution of LINE-1
to a non-normal distribution, and constitute a cluster in
the residuals plot in multivariate linear regression. Sec-
ond, LINE-1 extreme hypomethylation is associated with
younger age of onset, suggesting the presence of a previ-
ously-unrecognized, distinct cancer subtype. Third,
LINE-1 methylation level in colorectal cancer varies
greatly, even after accounting for various clinicopatho-
logic and other molecular variables. Our results support
enormous epigenomic diversity of colorectal cancers in
terms of LINE-1 methylation status and a possible subset
of mechanistically distinct LINE-1 extreme hypomethyla-
tors. These findings may have considerable clinical impli-
cations, since LINE-1 hypomethylated colon cancers
exhibit aggressive clinical behavior [20].
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